Search
Takeda Pharmaceutical Co Ltd
TAKAdd to Watchlist
18.890USD
-0.020-0.11%
Close 09-18 16:00（ET）
59.75BMarket Cap
49.29P/E TTM
After-hours 16:10 (ET)18.890USD-0.020-0.11%
After-hours 16:10 (ET)Takeda Pharmaceutical Co Ltd (TAK) Revenue Performance
Updated: Jun 30, 2026Last year, Takeda Pharmaceutical Co Ltd generated 4.42T USD for its biggest-performing segment, Pharmaceutical Business. The United States made the largest contribution, accounting for 2.16T USD last year. For the latest quarter, Takeda Pharmaceutical Co Ltd reported the revenue of 386.10B USD for the period ending 2026-06-30, which came from the top-performing segment, Gastrointestinal diseases. United States contributed the highest revenue, at 568.90B USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Pharmaceutical Business
Intellectual Property And Service Revenue
FY2026
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Pharmaceutical Business
4.42T(98.17%)
4.50T(98.13%)
4.16T(97.65%)
3.92T(97.39%)
3.30T(92.34%)
3.11T(97.11%)
3.20T(97.36%)
2.03T(96.62%)
1.69T(95.67%)
Intellectual Property And Service Revenue
82.61B(1.83%)
85.58B(1.87%)
100.11B(2.35%)
105.20B(2.61%)
273.28B(7.66%)
92.44B(2.89%)
87.04B(2.64%)
70.95B(3.38%)
76.69B(4.33%)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
Europe And Canada (Country)
Japan
Latin America
China (Country)
Others
Asia
Russia/CIS
United States
Europe
FY2026
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
United States
2.16T(48.05%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
598.34B(33.79%)
520.16B(30.03%)
514.42B(28.46%)
426.13B(23.97%)
374.53B(22.14%)
Europe And Canada (Country)
1.15T(25.44%)
1.06T(23.03%)
966.84B(22.68%)
842.67B(20.92%)
739.17B(20.71%)
666.18B(20.83%)
645.53B(19.61%)
405.64B(19.34%)
313.72B(17.72%)
279.69B(16.15%)
309.27B(17.11%)
325.29B(18.30%)
--(--)
Japan
433.11B(9.61%)
418.46B(9.13%)
451.39B(10.59%)
512.04B(12.71%)
658.98B(18.46%)
559.75B(17.50%)
592.79B(18.01%)
571.02B(27.23%)
580.35B(32.78%)
655.34B(37.84%)
688.09B(38.07%)
712.81B(40.09%)
733.88B(43.38%)
Latin America
254.13B(5.64%)
235.85B(5.15%)
198.10B(4.65%)
160.38B(3.98%)
128.47B(3.60%)
121.64B(3.80%)
143.46B(4.36%)
88.11B(4.20%)
75.66B(4.27%)
72.52B(4.19%)
68.39B(3.78%)
85.37B(4.80%)
81.25B(4.80%)
China (Country)
195.14B(4.33%)
191.74B(4.19%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Others
133.89B(2.97%)
128.85B(2.81%)
117.91B(2.77%)
95.18B(2.36%)
68.94B(1.93%)
68.52B(2.14%)
71.26B(2.17%)
38.31B(1.83%)
30.19B(1.71%)
33.99B(1.96%)
39.42B(2.18%)
35.49B(2.00%)
29.54B(1.75%)
Asia
98.67B(2.19%)
99.39B(2.17%)
261.22B(6.13%)
225.01B(5.59%)
196.96B(5.52%)
156.24B(4.89%)
165.40B(5.03%)
105.41B(5.03%)
104.03B(5.88%)
112.80B(6.51%)
125.96B(6.97%)
111.41B(6.27%)
85.37B(5.05%)
Russia/CIS
79.72B(1.77%)
72.36B(1.58%)
72.59B(1.70%)
88.43B(2.20%)
62.06B(1.74%)
57.56B(1.80%)
76.83B(2.33%)
59.74B(2.85%)
68.24B(3.85%)
57.55B(3.32%)
61.82B(3.42%)
81.32B(4.57%)
89.57B(5.29%)
United States
--(--)
2.38T(51.94%)
2.20T(51.50%)
2.10T(52.24%)
1.71T(48.04%)
1.57T(49.03%)
1.60T(48.49%)
828.99B(39.53%)
--(--)
--(--)
--(--)
--(--)
--(--)
Europe
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
297.55B(17.59%)